Novartis/Speedel Anti-Hypertensive Rasilez Could Reach Market By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for the oral renin inhibitor, submitted in the first quarter, seeks monotherapy and combination treatment claims.
You may also be interested in...
FDA Review Of Novartis’ Tekturna Set Back Three Months
Delay will allow agency to review new data on the impact of the first-in-class blood pressure medication on the colon.
FDA Review Of Novartis’ Tekturna Set Back Three Months
Delay will allow agency to review new data on the impact of the first-in-class blood pressure medication on the colon.
Speedel Could Market Blood Clot Candidate On Its Own
After Abbott announces it will not exercise a license-back option, the Swiss firm is considering several options.